HYTN Innovations Achieves GMP Certification for International Markets
VANCOUVER, British Columbia – HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF), a leading company in pharmaceutical-grade cannabis manufacturing, is excited to share its recent accomplishment of receiving digital Good Manufacturing Practices (GMP) certificates from Health Canada. This not only marks a significant milestone for the Kelowna-based facility but also expands its recognition in fulfilling GMP compliance for key markets including the United States, Bermuda, and Israel.
The Importance of GMP Compliance
The GMP certificates, which were officially requested by HYTN, play a crucial role in enhancing the credibility of drug registrations across various jurisdictions. They serve as a solid endorsement of HYTN’s manufacturing processes, especially in regions with less stringent regulatory frameworks. With the Drug Establishment Licence (DEL), HYTN is authorized to manufacture, package, and label non-sterile pharmaceuticals incorporating both cannabis and psilocybin, securing its status as a leader in global pharmaceutical markets.
Strategic Growth and Market Expansion
Jason Broome, COO of HYTN, stated, “Achieving GMP compliance in markets demanding it positions us strongly to support fresh drug registrations, facilitate clinical trials, and offer contract manufacturing services specifically for cannabis and psilocybin-based products.” This commitment underscores the company’s strategic approach to exploring global opportunities while delivering value to partners and stakeholders.
Currently, HYTN has an active presence with various commercial projects in Canada, the UK, Germany, and Australia. The recent certification for the U.S., Bermuda, and Israel is a testament to HYTN’s commitment to advancing GMP drug development and confirms its prominent role in high-quality, compliant manufacturing practices aimed at fostering international growth.
About HYTN Innovations Inc.
HYTN Innovations Inc. is at the forefront of the pharmaceutical sector, specializing in the formulation, manufacturing, marketing, and sale of psychoactive and psychotropic products. This includes cannabis-derived cannabinoids and psilocybe-derived tryptamines. Through its advanced development platform, HYTN aims to become a premier provider within federally regulated markets, leveraging innovative strategies to capitalize on market opportunities.
Understanding Good Manufacturing Practices (GMP)
GMP guidelines are essential for ensuring that manufacturing, testing, and quality assurance processes are in place, protecting consumer health by ensuring safety during consumption. Many countries have established GMP regulations that manufacturers are required to adhere to, creating a safeguard for product quality in the marketplace.
Commitment to Quality and Consumer Safety
HYTN's adherence to GMP standards reinforces its dedication to delivering safe and effective products. With its comprehensive approach and focus on innovative manufacturing practices, the company continues to build trust among its consumers and partners.
Contact Information
For more details about HYTN Innovations and its advancements, please reach out:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
Frequently Asked Questions
What is GMP certification?
GMP certification ensures that manufacturing processes comply with regulations that guarantee product quality and safety.
How does HYTN benefit from GMP certification?
The certification enables HYTN to register drugs in several jurisdictions and enhances their ability to conduct clinical trials and offer manufacturing services.
What markets is HYTN currently exploring?
HYTN is actively involved in projects across Canada, the UK, Germany, Australia, and is exploring opportunities in the U.S., Bermuda, and Israel.
What products does HYTN focus on?
HYTN focuses on the formulation and manufacturing of cannabis-derived cannabinoids and psilocybin-based products.
Who can I contact for more information about HYTN?
You can contact Elliot McKerr, CEO, or HYTN Investor Relations at 1.866.590.9289 or via email at investments@hytn.life.
